Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Adolescents and Young Adults With Functional Hypothalamic Amenorrhea
Latest Information Update: 07 Apr 2025
At a glance
- Drugs Romosozumab (Primary) ; Zoledronic acid
- Indications Amenorrhoea
- Focus Therapeutic Use
Most Recent Events
- 02 Apr 2025 Status changed from not yet recruiting to recruiting.
- 20 Mar 2025 Planned End Date changed from 1 Jun 2029 to 1 Apr 2029.
- 20 Mar 2025 Planned primary completion date changed from 1 Dec 2028 to 1 Oct 2028.